Q3 2017 EPS Estimates for Chemours Company (The) (CC) Decreased by Analyst

Chemours Company (The) (NYSE:CC) – Investment analysts at Jefferies Group dropped their Q3 2017 earnings estimates for shares of Chemours Company (The) in a report released on Wednesday. Jefferies Group analyst L. Alexander now expects that the specialty chemicals company will post earnings of $0.97 per share for the quarter, down from their previous forecast of $1.03. Jefferies Group has a “Buy” rating and a $60.00 price objective on the stock. Jefferies Group also issued estimates for Chemours Company (The)’s Q4 2017 earnings at $0.96 EPS, FY2017 earnings at $3.55 EPS and FY2020 earnings at $5.20 EPS.

Other research analysts also recently issued research reports about the stock. UBS AG reissued a “sell” rating and issued a $36.00 price objective (up previously from $35.00) on shares of Chemours Company (The) in a research report on Wednesday, June 14th. Susquehanna Bancshares Inc lifted their price objective on shares of Chemours Company (The) from $45.00 to $55.00 and gave the company a “positive” rating in a research report on Monday, May 15th. Zacks Investment Research downgraded shares of Chemours Company (The) from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. J P Morgan Chase & Co lifted their price objective on shares of Chemours Company (The) to $55.00 and gave the company an “overweight” rating in a research report on Friday. Finally, BidaskClub raised shares of Chemours Company (The) from a “hold” rating to a “buy” rating in a research report on Wednesday, July 12th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Chemours Company (The) currently has a consensus rating of “Buy” and an average price target of $46.25.

WARNING: This report was first published by BNB Daily and is owned by of BNB Daily. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/19/q3-2017-eps-estimates-for-chemours-company-the-cc-decreased-by-analyst-updated.html.

Shares of Chemours Company (NYSE CC) opened at 49.77 on Monday. Chemours Company has a 12-month low of $8.86 and a 12-month high of $51.51. The company has a market capitalization of $9.21 billion, a PE ratio of 32.55 and a beta of 3.63. The firm’s 50-day moving average is $41.37 and its 200-day moving average is $37.03.

Chemours Company (The) (NYSE:CC) last released its quarterly earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.02. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The company had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the prior year, the company earned $0.27 earnings per share. The business’s quarterly revenue was up 14.8% compared to the same quarter last year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Thursday, August 17th will be issued a dividend of $0.03 per share. This represents a $0.12 annualized dividend and a dividend yield of 0.24%. The ex-dividend date is Tuesday, August 15th. Chemours Company (The)’s payout ratio is 8.11%.

In related news, VP Erich Parker sold 4,908 shares of Chemours Company (The) stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $45.53, for a total transaction of $223,461.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Paul Kirsch sold 19,036 shares of Chemours Company (The) stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $41.42, for a total transaction of $788,471.12. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Financial Architects Inc increased its stake in shares of Chemours Company (The) by 1,230.3% in the second quarter. Financial Architects Inc now owns 2,940 shares of the specialty chemicals company’s stock valued at $111,000 after buying an additional 2,719 shares during the last quarter. Benjamin F. Edwards & Company Inc. increased its stake in shares of Chemours Company (The) by 2,138.8% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 3,112 shares of the specialty chemicals company’s stock valued at $118,000 after buying an additional 2,973 shares during the last quarter. Ropes Wealth Advisors LLC increased its stake in shares of Chemours Company (The) by 82.4% in the first quarter. Ropes Wealth Advisors LLC now owns 3,099 shares of the specialty chemicals company’s stock valued at $119,000 after buying an additional 1,400 shares during the last quarter. Schroder Investment Management Group bought a new stake in shares of Chemours Company (The) during the first quarter valued at approximately $156,000. Finally, Cypress Capital Management LLC WY increased its stake in shares of Chemours Company (The) by 1.9% in the first quarter. Cypress Capital Management LLC WY now owns 4,196 shares of the specialty chemicals company’s stock valued at $162,000 after buying an additional 80 shares during the last quarter. 75.21% of the stock is owned by institutional investors and hedge funds.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Earnings History and Estimates for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply